Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Oncolytics Biotech provided a GOBLET Phase 1/2 study update: enrollment is complete, final Cohort 4 results are expected in Q4 2026, and initial Cohort 5 (first-line metastatic PDAC) results are expected in the first half of 2027. The company will receive the final payment under its PanCAN grant this quarter and is winding down the broader GOBLET study infrastructure while remaining patients continue treatment and follow-up.
Key figures
- Drug Name
- pelareorep
- Guidance
- Final Cohort 4 results expected Q4 2026; initial Cohort 5 results expected H1 2027
- Phase Of Trial
- Phase 1/2
- Study sites
- 17
- Patients treated to date
- over 1,200
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.